Plasma Visfatin Concentrations in Subjects with Type 1 Diabetes Mellitus

Toruner F. S., Altinova A., Bukan N., Arslan E., Akbay E., Ersoy R., ...Daha Fazla

HORMONE RESEARCH, cilt.72, sa.1, ss.33-37, 2009 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 72 Sayı: 1
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1159/000224338
  • Dergi Adı: HORMONE RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
  • Sayfa Sayıları: ss.33-37
  • Anahtar Kelimeler: Type 1 diabetes mellitus, Visfatin, Hemoglobin A1c, Lipids, Diabetes duration, COLONY-ENHANCING FACTOR, ADIPOCYTOKINE VISFATIN, GENE-EXPRESSION, WEIGHT-LOSS, GLUCOSE, PROTEIN, APELIN, WOMEN, FAT
  • Gazi Üniversitesi Adresli: Evet

Özet

Background/Aims: Visfatin is a recently discovered adipokine, and its circulating concentrations have not been adequately studied in type 1 diabetes mellitus (DM). Therefore, this study was designed to examine plasma visfatin levels in type 1 diabetic patients and to determine the relationships between visfatin and duration of diabetes, body mass index, glycemic control, insulin dosage and lipid profile. Methods: Forty-eight patients with type 1 DM and 26 healthy controls were investigated. Results: Type 1 diabetic patients had significantly low visfatin levels compared with controls (18.8 +/- 1.7 vs. 20.2 +/- 0.3 ng/ ml; p < 0.0001). Visfatin levels were comparable between patients with a short duration of diabetes ( ! 10 years) and patients with a long duration of diabetes (>= 10 years) (18.9 +/- 1.7 vs. 18.2 +/- 2.0 ng/ ml; p > 0.05). There was a significant correlation between visfatin and hemoglobin A1c (HbA1c) even after the adjustment for age, sex, body mass index and duration of diabetes (r = -0.48, p = 0.005) in the patient group. Multivariate analysis showed that significant determinants of visfatin concentrations were HbA1c and duration of diabetes (r(2) = 0.27). Conclusion: These data emphasize that plasma visfatin concentrations are lower in patients with type 1 DM and related to glycemic control reflected by HbA1c. Copyright (C) 2009 S. Karger AG, Basel